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Cowchock Syndrome Is Associated
with a Mutation in Apoptosis-Inducing Factor
Carlo Rinaldi,1,* Christopher Grunseich,1 Irina F. Sevrioukova,2 Alice Schindler,1 Iren Horkayne-Szakaly,3
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Carsten Bo¨nnemann,1 Leslie G. Biesecker,8 Daniele Ghezzi,4 Massimo Zeviani,4 and
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Cowchock syndrome (CMTX4) is a slowly progressive X-linked recessive disorder with axonal neuropathy, deafness, and cognitive
impairment. The disease locus was previously mapped to an 11 cM region at chromosome X: q24-q26. Exome sequencing of an affected
individual from the originally described family identified a missense change c.1478A>T (p.Glu493Val) in AIFM1, the gene encoding
apoptosis-inducing factor (AIF) mitochondrion-associated 1. The change is at a highly conserved residue and cosegregated with
the phenotype in the family. AIF is an FAD-dependent NADH oxidase that is imported into mitochondria. With apoptotic insults, a
N-terminal transmembrane linker is cleaved off, producing a soluble fragment that is released into the cytosol and then transported
into the nucleus, where it triggers caspase-independent apoptosis. Another AIFM1 mutation that predicts p.Arg201del has recently
been associated with severe mitochondrial encephalomyopathy in two infants by impairing oxidative phosphorylation. The
c.1478A>T (p.Glu493Val) mutation found in the family reported here alters the redox properties of the AIF protein and results in
increased cell death via apoptosis, without affecting the activity of the respiratory chain complexes. Our findings expand the spectrum
of AIF-related disease and provide insight into the effects of AIFM1 mutations.Charcot-Marie-Tooth disease (CMT) defines a clinically
and genetically heterogeneous group of hereditary periph-
eral neuropathies characterized by chronic motor and
sensory impairment. Charcot-Marie-Tooth disease is the
most common hereditary neuromuscular disorder, with
a prevalence of ~1 in 2,500 people.1 Approximately 7%–
10% of CMT is inherited as an X-linked trait (CMTX).2,3
Among the five known CMTX loci, the disease-causing
mutations have been identified only for CMTX1 (MIM
304040)4 and CMTX5 (MIM 311850).5
In 1985, Cowchock et al. reported a large Italian-Amer-
ican family with a slowly progressive, childhood-onset,
X-linked recessive axonal motor and sensory neuropathy
associated with deafness and cognitive impairment.6 By
linkage analysis, the disease locus was mapped to an 11
cM region at chromosome X: 116,500,000–130,400,000
(CMTX4 [MIM 310490]).7,8 We recently re-evaluated this
family and identified a mutation in a candidate gene in
this interval. The subjects were enrolled in an institutional
review board-approved protocol of the National Institute
of Neurological Disorders and Stroke (NINDS), and
informed consent was obtained from all living subjects.
The most consistently observed clinical abnormalities
were distal muscle wasting, weakness, and sensory loss,
with lower limb greater than upper limb involvement.
Only males displayed the phenotype, consistent with an
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The American Joudescribed previously,6 electrophysiological studies in
affected individuals showed evidence of motor more
than sensory axonal neuropathy. Bilateral sensorineural
hearing loss was also present in three subjects. Diminished
intellectual abilities had been noted in several affected
individuals since childhood.
Laboratory investigations in two affected individuals
(III-6 and III-9) showed elevation of serum transaminases
(up to 23), lactate dehydrogenase (up to 440 U/l, normal
values 113–226), and creatine kinase (up to 1,169 U/l,
normal values 52–386). Blood pyruvate and free and total
carnitine were normal. Cranial MRI in two subjects (III-3
and III-9) showed multiple punctate T2 hyperintensities
in the supratentorial white matter (Figure 1B). Muscle
biopsy (left biceps; subject III-9) showed modest signs of
neurogenic atrophy (Figures 1C–1E), with no ragged-red
fibers by modified Gomori trichrome staining and no
abnormalities in histochemical staining for cytochrome
oxidase and succinate dehydrogenase (not shown). Elec-
tron microscopy showed an increased number of mito-
chondria mainly in the subsarcolemmal areas, with
moderate abnormality of mitochondrial shape and
internal structure (Figure 1F).
We performed exome capture on one affected subject by
using SureSelect Human All Exome Kit v.1 (Agilent Tech-
nologies) and sequencing by using a Genome Analyzer
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Figure 1. Pedigree, Brain Imaging, and
Skeletal Muscle Analysis and Sanger
Sequencing
(A) Pedigree of the family. White, unaf-
fected; black, affected.
(B) Fluid-attenuated inversion recovery
(FLAIR) magnetic resonance imaging on
a transverse section of supratentorial brain
of an affected individual showingmultiple
punctate hyperintensities in the white
matter (arrows; subject III-6).
(C–E) Muscle biopsy showing variation in
fiber size (hematoxylin and eosin staining,
C), esterase-positive angular atrophic myo-
fibers (esterase staining, D), and fiber
grouping with some targetoid fibers (nico-
tinamide adeninedinucleotide-tetrazolium
reductase, E) (subject III-9). (F) Electron
microscopic image of muscle showing
variation in shape and increase in number
of mitochondria, mainly in the subsarco-
lemmal areas (subject III-9).
(G) Chromatograms of AIFM1 showing
the c.1478A>T (p.Glu493Val) variant
(asterisk) in an affected individual (hemi-
zygote) and a carrier (heterozygote).targeted regions with a read depth >203. Read alignment
was performed to the human genome assembly hg19.
We filtered variants to exclude HapMap SNPs that were
present in dbSNP132 and that had an average heterozy-
gosity greater than 0.02. This approach left as a single-
candidate variant the substitution c.1478A>T (RefSeq
NM_004208.3; GRCh37/hg19 chrX: 129,265,745T>A),
within exon 14 of AIFM1 (MIM 300169), which predicts
a p.Glu493Val change.
To confirm the AIFM1 mutation, we used Sanger
sequencing to screen five affected (II-3, III-3, III-5, III-7,
and III-9) and nine unaffected (I-1, I-2, II-1, II-2, II-5, II-8,
III-2, and III-4) family members (Figure 1A). All clinically
affected subjects were hemizygous and all mothers of
affected individuals were heterozygous for the c.1478A>T
(p.Glu493Val) variant (Figure 1G). None of the other unaf-
fected subjects had this variant. Thus, the mutation in
AIFM1 completely cosegregated with the CMT phenotype.
The Glu493 residue is conserved across multiple species
(Figure S1 available online) and the Val493 variant was
absent in 712 control individuals in the ClinSeq cohort.9
No mutation in AIFM1 was found in 102 unrelated males
with CMT of unknown genetic cause.1096 The American Journal of Human Genetics 91, 1095–1102, December 7, 2012AIF, a phylogenetically conserved
mitochondrial flavoprotein, is one of
the key caspase-independent death
effectors.10–12 The AIF precursor
protein is a nuclear-encoded 67 kDa
polypeptide, which, after cleavage of
the N-terminal mitochondrial target-
ing sequence, is posttranslationally
inserted into the inner mitochondrial
membrane, with the N terminusfacing the matrix and the C-terminal catalytic domain
exposed to the intermembrane space.13 Upon apoptotic
insult, the membrane linker of AIF is cleaved off, and
a soluble 57 kDa C-terminal fragment is released into
the cytosol and transported into the nucleus, where it trig-
gers caspase-independent apoptosis with chromatin
condensation and DNA fragmentation.10 Although the
apoptotic function of AIF has been extensively investi-
gated, the physiological role of the protein in normal
mitochondria remains unclear. AIF has been proposed to
function as a superoxide-generating NADH oxidase or elec-
tron transferase.14,15 Despite recent in vivo analyses of the
metabolic changes caused by AIF deficiency or defects,
neither the substrates nor the acceptor(s) of its redox
activity have been identified thus far. When its cofactor
FAD is incorporated, the protein has a 100-fold preference
for NADH over NADPH and forms dimeric FADH-NAD
charge-transfer complexes (CTCs), which are inefficient
for electron transfer. Formation of CTC reduces the suscep-
tibility of the N terminus to proteolysis and weakens
the AIF-DNA interaction, two events critical for initiation
of caspase-independent apoptosis.16,17 Further studies
have suggested that AIF may act as a redox sensor with
Figure 2. Structural Comparison of the Wild-Type and p.Glu493Val Mutant of AIF
The p.Glu493Val substitution was introduced into the human AIF1 expression plasmid by Stratagene QuikChange kit. Expression,
purification, and removal of the C-terminal six-histidine affinity tag were carried out as described previously.18
(A) Position of Glu493 (indicated by an arrow) in oxidized human AIFwt (PDB code 1M6I). FAD is shown in yellow and a partially
disordered regulatory peptide is in pink.
(B) Water-bridged contacts involving Glu493 hold the 512–533 helical fragment of the regulatory peptide (pink) close to the active site.
(C) Charge distribution near the flavin cofactor. Positively and negatively charged residues are depicted in blue and red, respectively.
Glu493 is 10 A˚ away from FAD and is part of an acidic cluster adjacent to the isoalloxazine ring.
(D) Superposition of the structures of the wild-type (gray, PDB code 1M6I) and Glu493Val mutant of human AIF (green, PDB code 4FDC).
The structure of AIFE493V was solved at 2.4 A˚ resolution. Data collection and refinement statistics are given in Table S1. The valine side
chain is shown in cyan.
(E) A magnified view at the region of AIF near the site of the p.Glu493 residue demonstrating that the substitution does not alter the
structure near the active site of AIF.
(F) The Glu493Val substitution changes both the surface profile and electrostatic potential, which may affect solvent accessibility and
redox properties of FAD.interrelated physiologic and apoptotic functions.18 Insight
into the normal function of AIF comes from the Harlequin
(Hq) mouse, a spontaneous model of AIF deficiency result-
ing from retroviral insertion into Aifm1.19 The Hq model
has 80% reduction in normal AIF protein levels and
decreased complex I and III activities in affected tissues,
suggesting that AIF may control the biogenesis and
maintenance of the respiratory complexes.20,21 Recently,
a c.del601_603 AIFM1 mutation predicted to cause
p.Arg201del was reported in two male infants with severe
progressive mitochondrial encephalomyopathy, multiple
defects of the respiratory chain activities, and increased
caspase-independent apoptosis.22 A second pathological
AIFM1 mutation, c.923G>A, which predicts p.Gly308Glu,
was associated with prenatal ventriculomegaly and infan-
tile encephalomyopathy, primarily because of defects in
the mitochondrial respiratory chain.23 Gly308 is located
in a conserved NADH-binding region, suggesting thatThe American Jouthis function may be compromised by the p.Gly308Glu
substitution.
The negatively charged residue Glu493 mutated in the
family reported here is not directly involved in FAD or
NADH binding but is only 10 A˚ away from the isoalloxa-
zine ring that is the redox moiety of FAD. In oxidized
AIF, Glu493 is buried and assists in folding of the
C-terminal regulatory insertion by mediating water-
bridged contacts between the 532–534 and 581–584
peptides (Figures 2A and 2B). The Glu493Val substitution
may weaken these interactions and lead to amore unstable
protein conformation. In NADH-reduced AIF, the region
surrounding Glu493 becomes exposed to solvent.16 As
seen in Figure 2C, this surface is highly charged, with
several acidic residues clustering near the pyrimidine
portion of the isoalloxazine ring. This charge distribution
is known to define the redox potential of FAD and, conse-
quently, the flavoprotein reactivity. The X-ray structure ofrnal of Human Genetics 91, 1095–1102, December 7, 2012 1097
Figure 3. Comparison of the Redox and
Molecular Properties of the Wild-Type
andp.Glu493Valandp.Arg201delMutants
of AIF
(A) Anaerobic titration of AIFE493V with
NADH. Similar to the wild-type protein,
the p.Glu493Val variant binds NADH
tightly and produces a FADH-NAD
charge-transfer complex (CTC) absorbing
in the long-wavelength region. Inset
shows that an equimolar amount of
NADH is required to fully reduce FAD.
(B) Kinetics of AIF reduction with NADH.
Proteins were mixed with NADH in
a stopped flow spectrophotometer, and
reduction of FAD was monitored at
452 nm. The derived kinetic parameters
are given in Table 1.
(C) Kinetics of oxidation of NADH-reduced
AIF. Proteins were reduced with a 4-fold
excess of NADH before exposure to atmo-
spheric oxygen. Flavin oxidation was
monitored at 452 nm.
(D) Effect of pH on the kinetics of AIF
reduction with NADH.
(E) Comparison of DNA binding by wild-
type and mutant AIF. Equal amounts of
protein (100 mg) were incubated for
15 min with 250 ng of 100 bp DNA ladder
(New England Biolabs) in the absence and
presence of a 20-fold excess of NADH.
After separation on a 2% agarose gel,
DNA was visualized with ethidium
bromide. Lane 1 is a control (DNA only).oxidized p.Glu493Val AIF shows that this substitution at
position 493 does not affect protein folding but perturbs
the electrostatic surface potential near the redox center
and changes the surface profile (Figures 2D–2F). This, in
turn, could increase solvent accessibility of FAD and affect
the redox reactivity of AIF.
To better understand the pathogenicity of the
p.Glu493Val substitution identified in the family with
CMTX, several properties of the recombinant mutant
protein were analyzed and compared to those of the
wild-type AIF and the previously reported p.Arg201del
variant.22 The absorbance spectrum, extinction coeffi-
cient, and midpoint redox potential of AIF were not
affected by the p.Glu493Val substitution. Similar to the
wild-type AIF, p.Glu493Val AIF has high affinity for
NADH, binds the cofactor tightly and in a stoichiometric
fashion, and forms CTC upon reduction (Figure 3A). This
implies that the NADH binding site in p.Glu493Val AIF is
preserved. Nevertheless, a subtle difference in circular
dichroism spectra, slightly higher flavin fluorescence,1098 The American Journal of Human Genetics 91, 1095–1102, December 7, 2012and a distinct proteolytic pattern of
p.Glu493Val AIF were observed
(Figures S2A–S2C), indicating struc-
tural dissimilarities between wild-
type and mutant proteins.
The most notable changes caused
by the p.Glu493Val substitutionwere observed in electron transfer ability. First,
p.Glu493Val AIF has lower KM for NADH (by 20%) than
does wild-type AIF and becomes reduced by NADH 4-fold
faster (Figure 3B and Table 1). Second, the dimeric CTC
produced by wild-type AIF reacts with oxygen slowly and
is relatively stable,18 whereas the half-life (t1/2) of CTC
produced by p.Glu493Val AIF is one eighth that produced
by the wild-type protein (Figure 3C and Table 1). Because
p.Glu493Val AIF retains its ability to dimerize upon reduc-
tion with NADH (Figure S2D), an effect of the p.Glu493Val
substitution on redox-linked dimer formation can be ruled
out. Finally, p.Glu493Val AIF more efficiently transfers
electrons to small electron-accepting molecules and cyto-
chrome c (compare the kcat/KM
NADH values in Table 1,
which reflect the enzyme efficiency), but these redox reac-
tions are partially uncoupled (~10% for p.Glu493Val AIF
versus 1%–2% for wild-type AIF).
Another distinct feature of p.Glu493Val AIF is the pH
dependence of its reaction with NADH. Unlike wild-type
AIF, which accepts the hydride atom from NADH in
Table 1. Redox Properties and Activities of the Wild-Type and
Mutants of Mature Human AIF
WT p.Glu493Val p.Arg201del
ket
NADH (s1)a 0.98 5 0.02 3.95 0.1 23 5 0.4
KM
NADH (mM) 1.53 5 0.06 1.23 5 0.05 0.23 5 0.02
t1/2
CTC (hr)b 11 1.4 3.4
kox
NADH (min1)c 0.015 5 0.002 0.12 5 0.02 0.06 5 0.01
DCIP
kcat (min
1) 137 5 18 3355 32 3945 28
KM
DCIP (mM) 2025 36 97 5 20 16 5 3
KM
NADH (mM) 0.74 5 0.12 0.16 5 0.04 0.14 5 0.02
kcat/ KM
NADH
(mM1 min1)
185 2,094 2,814
K3Fe(CN)6
kcat (min
1) 314 5 25 7455 30 1,464 5 92
KM
K
3
Fe(CN)
6 (mM) 28 5 5 26 5 5 68 5 6
KM
NADH (mM) 0.61 5 0.10 0.26 5 0.05 0.20 5 0.03
kcat/KM
NADH
(mM1 min1)
515 2,865 7,320
Cytochrome c
kcat (min
1) 54 5 15 35 5 5 39 5 2
KM
cyt c (mM) 26 5 13 28 5 8 94 5 10
KM
NADH (mM) 0.27 5 0.02 0.15 5 0.02 0.07 5 0.01
kcat/ KM
NADH
(mM1 min1)
200 233 557
All activities were determined in 50 mM phosphate buffer (pH 7.4) at 25C.
aThe rate constant for the AIF reduction by NADH was determined by stopped
flow spectrophotometry at 25C.
bThe half-life of the FADH2-NAD charge-transfer complex (CTC) was deter-
mined at 25C in the presence of 15 mM AIF and 60 mM NADH.
cThe rate of NADH oxidation by AIF was determined at 25C.a pH-independent manner, the rate of p.Glu493Val AIF
reduction is notably affected and increases by 6-fold at
higher pH (Figure 3D). Such pH dependence indicates
that reduction of p.Glu493Val AIF is associated with
proton consumption and may lead to the formation of
a neutral FAD hydroquinone (FADH2). The latter redox
species is less thermodynamically stable than an anionic
hydroquinone (FADH) formed by wild-type AIF, which
may be the reason for faster oxidation of p.Glu493Val
AIF by electron acceptors. Based on these experimental
data, we conclude that the Glu493 residue controls proton
accessibility to the flavin moiety and modulates the redox
reactivity of AIF.
Importantly, the destabilization and faster oxidation of
the p.Glu493Val AIF-NADH complexes in vivo can deter-
mine the accumulation of AIF monomers that are more
prone to N-terminal proteolysis and release of the soluble,
apoptogenic fragment.16,18 Similar to p.Arg201del AIF,22
the truncated apoptogenic form of p.Glu493Val AIF has
higher affinity for DNA than the wild-type proteinThe American Jou(Figure 3E). The lack of an inhibiting effect of NADH on
the p.Glu493Val AIF-DNA interaction, which is observed
for wild-type AIF,18 was probably due to rapid and
complete oxidation of p.Glu493Val AIF before the gel retar-
dation experiment was over.
We then investigated the consequences of the
p.Glu493Val substitution in cultured skin fibroblasts and
skeletal muscle derived from an affected individual. We
first showed that the levels of mutant AIF in fibroblasts
from subject III-3 were similar to those of wild-type AIF
in control cells (Figure S3). Next, in order to test whether
the p.Glu493Val AIF variant is directly linked to impaired
oxidative phosphorylation, we analyzed the activity of
the respiratory chain complexes in mutant fibroblast cell
lines grown for 48 hr in a galactose-rich (5 mM), glucose-
free medium, a condition that forces cells to rely for energy
on mitochondrial respiration rather than glycolysis. The
activity of respiratory chain complexes in fibroblasts
derived from an affected individual was not reduced
compared to carrier and controls (not shown). Likewise,
no impairment in the respiratory chain activities was de-
tected in a muscle biopsy from subject III-9 (not shown).
Mitotracker-based visualization (Invitrogen) was used to
assess fragmentation of the mitochondrial network, which
is a well-documented alteration related to reduced fusion
of mitochondrial membranes. No difference could be de-
tected in galactose-grown mutant fibroblasts compared to
control, supporting the hypothesis that the mutation
does not grossly perturb mitochondrial function (not
shown).
In order to detect DNA fragmentation, which is a hall-
mark of apoptosis, we performed TUNEL assay in muscle
biopsy. Numerous apoptotic cells were present in the
sample from the affected individual, whereas little to no
staining was detected in healthy control muscle
(Figure 4A).
Because AIF is a caspase-independent death effector, we
treated p.Glu493Val AIF mutant and wild-type AIF control
fibroblasts with staurosporine, a protein-kinase C inhibitor
that induces cell death through the intrinsic, mitochon-
dria-mediated pathway, at 1 mM for 2 hr, enough to trigger
some of the early changes of apoptotic execution like the
compaction of nuclear chromatin without resulting in
cell death (Figure S4). We observed a much higher number
of morphologically altered nuclei in staurosporine-treated
p.Glu493Val AIF fibroblasts as compared to wild-type AIF
cells (Figure 4B). In cells pretreated with the general cas-
pase inhibitor z-VAD-FMK (100 mM for 0.5 hr), the stauro-
sporine-induced nuclear abnormalities dropped to less
than 10% in control fibroblasts, but remained as high as
50% in p.Glu493Val AIF mutant cells (Figure 4B), suggest-
ing prominent activation of the caspase-independent, AIF-
specific cell death pathway.
In order to gain insight into p.Glu493Val AIF localiza-
tion in vivo, 8 mm muscle slices from subject III-9 and
a healthy control were immunostained for AIF. Interest-
ingly, more AIF-positive nuclear inclusions were detected,rnal of Human Genetics 91, 1095–1102, December 7, 2012 1099
Figure 4. Caspase-Independent Apoptosis and Nuclear Localization of p.Glu493Val AIF
(A) TUNEL and DAPI staining of skeletal muscle nuclei from an affected subject (mut) and a control (WT). A normal biopsy treated with
DNase was used a positive control (Cþ). Numerous TUNEL-positive nuclei are present in the affected subject, whereas no TUNEL-posi-
tive nuclei are seen in the control. Quantification of TUNEL-positive nuclei (n ¼ 100) on the right.
(B) Quantification of altered nuclei in control fibroblasts (WT) and in fibroblasts from an affected individual (mut) after treatment with
staurosporine (1 mM for 2 hr) in presence or absence of Z-VAD-fmk (100 mM for 0.5 hr).
(C) AIFM1 (1:1,000; Millipore, AB16501) immunostaining of cross section of muscle biopsy showing nuclear localization of mutant AIF
in a subject hemizygous for p.Glu493Val (mut) compared to control (WT). Nuclei andmitochondria were counterstained with DAPI and
mouse Tom20 antibody (BD Transduction Laboratory), respectively. AIF-positive nuclei were counted and normalized to the total
number of DAPI-stained nuclei from three random and nonoverlapping fields (mean; SEM; p < 0.01).
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indicating that mutant p.Glu493Val AIF has higher
propensity to translocate into the nucleus (Figure 4C).
In conclusion, we found that a missense mutation in
AIFM1 causes Cowchock syndrome, a form of X-linked
recessive axonal motor and sensory neuropathy with
sensorineural hearing loss and cognitive impairment.
According to our analysis, p.Glu493Val AIF has slight
structural changes and an abnormal propensity to NADH
reduction and O2 oxidation, probably because of changes
in the FAD protonation state. Faster oxidation of
p.Glu493Val AIF could lead to accumulation of AIF mono-
mers, which translocate into the nucleus, where they
trigger caspase-independent apoptosis. Interestingly, com-
pared to the previously described p.Arg201del substitu-
tion,22 the variant reported here alters the structure and
redox properties of AIF to a milder extent (Figures 3B–3D
and Table 1), which is consistent with a less severe clinical
phenotype. Also, whereas oxidative phosphorylation
(OXPHOS) failure is thought to play a major role in the
pathophysiology of the p.Arg201del AIF-related syn-
drome,22 the mechanism of damage in CMTX4 appears
to be OXPHOS independent and primarily mediated by
increased caspase-independent apoptosis.
Our identification of AIFM1 as a gene mutated in CMT
considerably broadens the phenotypic spectrum associ-
ated with AIFM1 mutations. The results presented here
also shed new light on the multiple pathogenic mecha-
nisms in AIF-related diseases.
Analysis of additional AIFM1 mutations may help to
further unravel the pathophysiology of AIF defects, to
identify proteins dependent on AIF activity, and to deter-
mine the exact role of AIF in mitochondria. Considering
the wide range and importance of the cellular processes
regulated by AIF, better understanding of AIF functions
may have broad and unexpected implications in both
medicine and cell biology.
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